Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05980598
Title TransCon (TC) TLR7/8 Agonist, TC IL-2 beta/gamma, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma (BelieveIT-201)
Acronym BelieveIT-201
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Ascendis Pharma Oncology Division A/S
Age Groups: senior | adult
Covered Countries USA | ITA | ESP | DEU

No variant requirements are available.